University of Texas MD Anderson Cancer Center Houston, Texas
John Charles Cain Distinguished Chair Department of Clinical Cancer Prevention
Developing effective, targeted therapies for the prevention of triple-negative breast cancer
During the past ten years, incidence of breast cancer in the United States has steadily increased. Preventative drugs that target essential pathways involved in breast cancer development have been extensively studied. For example, endocrine therapies that target estrogen receptor (ER), can prevent the formation of ER-positive breast cancer. However, these therapies do not prevent the formation of ER-negative breast cancer. Because ER-negative breast cancers, including the aggressive triple-negative breast cancer (TNBC) subtype, are associated with poorer outcomes, there is a critical need to develop effective therapies that can prevent ER-negative and triple-negative breast cancer. Dr. Brown and his team are seeking to develop effective, targeted therapies that can prevent these subtypes of breast cancer.
The team has found that the specific activator of retinoid X receptor (RXR), IRX4204, delays the formation of tumors in laboratory models of ER-negative and triple-negative breast cancer. IRX4204 can increase the presence of immune cells in triple-negative tumors, and treatment with targeted therapies, such as PARP inhibitors, checkpoint inhibitors, and mTOR inhibitors can delay but not prevent tumor formation in triple-negative models. The mechanism by which these drugs delay tumor formation is still unknown.
The team will identify key molecules and pathways responsible for resistance to preventative agents in triple-negative tumor models and demonstrate that targeted therapies in combination with immune therapies can overcome tumor resistance and prevent tumor formation in laboratory models.
Powel Brown, MD, PhD is a molecular biologist and breast medical oncologist at the University of Texas, MD Anderson Cancer Center, where he is Chair of the Department of Clinical Cancer Prevention. His research interests lie in developing therapies for the prevention of breast cancer and focuses on developing molecularly targeted therapies for the treatment and prevention of triple-negative breast cancer (TNBC). He has been the Principal Investigator of MD Anderson’s National Institute of Health (NIH)/National Cancer Institute (NCI)-funded PREVENT program which supports preclinical research testing and prevention interventions. He has also directed an NCI-funded Cancer Prevention Consortium to conduct clinical cancer prevention trials. Dr. Brown’s leadership roles include serving as Leader of the Cancer Prevention Program at the MD Anderson Cancer Center and President of the International Society of Cancer Prevention, and he is a Fellow of the American Association for the Advancement of Science (AAAS).
If not for BCRF we would be unable to conduct our research to identify novel immune strategies for the prevention of breast cancer in high-risk women.
2004
Please remember BCRF in your will planning. Learn More
